5 results on '"Saal, Lao H."'
Search Results
2. The Retinoblastoma Gene Undergoes Rearrangements in BRCA1-Deficient Basal-like Breast Cancer.
- Author
-
Jönsson, Göran, Staaf, Johan, Vallon-Christersson, Johan, Ringnér, Markus, Gruvberger-Saal, Sofia K., Saal, Lao H., Holm, Karolina, Hegardt, Cecilia, Arason, Adalgeir, Fagerholm, Rainer, Persson, Camilla, Grabau, Dorthe, Johnsson, Ellinor, Lövgren, Kristina, Magnusson, Linda, Heikkilä, Päivi, Agnarsson, Bjarni A., Johannsson, Oskar T., Malmström, Per, and Fernö, Mårten
- Subjects
- *
BREAST cancer research , *GENE expression , *BRCA genes , *PROMOTERS (Genetics) , *METHYLATION - Abstract
Breast tumors from BRCA1 germ line mutation carriers typically exhibit features of the basal-like molecular subtype. However, the specific genes recurrently mutated as a consequence of BRCA1 dysfunction have not been fully elucidated. In this study, we used gene expression profiling to molecularly subtype 577 breast tumors, including 73 breast tumors from BRCA1/2 mutation carriers. Focusing on the RB1 locus, we analyzed 33 BRCA1- mutated, 36 BRCA2-mutated, and 48 non-BRCA1/2--mutated breast tumors using a custom-designed high-density oligomicroarray covering the RB1 gene. We found a strong association between the basal-like subtype and BRCA1-mutated breast tumors and the luminal B subtype and BRCA2-mutated breast tumors. RB1 was identified as a major target for genomic disruption in tumors arising in BRCA1 mutation carriers and in sporadic tumors with BRCA1 promoter methylation but rarely in other breast cancers. Homozygous deletions, intragenic breaks, or microdeletions were found in 33% of BRCA1-mutant tumors, 36% of BRCA1 promoter--methylated basal-like tumors, 13% of non-BRCA1--deficient basal-like tumors, and 3% of BRCA2-mutated tumors. In conclusion, RB1 was frequently inactivated by gross gene disruption in BRCA1 hereditary breast cancer and BRCA1-methylated sporadic basal-like breast cancer but rarely in BRCA2 hereditary breast cancer and non-BRCA1--deficient sporadic breast cancers. Together, our findings show the existence of genetic heterogeneity within the basal-like breast cancer subtype that is based upon BRCA1 status. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
3. p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.
- Author
-
Pappas K, Xu J, Zairis S, Resnick-Silverman L, Abate F, Steinbach N, Ozturk S, Saal LH, Su T, Cheung P, Schmidt H, Aaronson S, Hibshoosh H, Manfredi J, Rabadan R, and Parsons R
- Subjects
- AMP-Activated Protein Kinase Kinases, Binding Sites genetics, Cell Line, Tumor, Forkhead Box Protein O1 genetics, Gene Expression Regulation, Neoplastic, Haploinsufficiency genetics, Histone Demethylases genetics, Humans, MicroRNAs genetics, Mutation, Neoplasms pathology, Nuclear Proteins genetics, PTEN Phosphohydrolase genetics, Protein Binding, Protein Serine-Threonine Kinases genetics, Receptors, TNF-Related Apoptosis-Inducing Ligand genetics, Signal Transduction genetics, Cell Transformation, Neoplastic genetics, Neoplasms genetics, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Proteins genetics
- Abstract
TP53 is the most commonly mutated tumor suppressor gene and its mutation drives tumorigenesis. Using ChIP-seq for p53 in the absence of acute cell stress, we found that wild-type but not mutant p53 binds and activates numerous tumor suppressor genes, including PTEN, STK11(LKB1), miR-34a, KDM6A(UTX), FOXO1, PHLDA3 , and TNFRSF10B through consensus binding sites in enhancers and promoters. Depletion of p53 reduced expression of these target genes, and analysis across 18 tumor types showed that mutation of TP53 associated with reduced expression of many of these genes. Regarding PTEN, p53 activated expression of a luciferase reporter gene containing the p53-consensus site in the PTEN enhancer, and homozygous deletion of this region in cells decreased PTEN expression and increased growth and transformation. These findings show that p53 maintains expression of a team of tumor suppressor genes that may together with the stress-induced targets mediate the ability of p53 to suppress cancer development. p53 mutations selected during tumor initiation and progression, thus, inactivate multiple tumor suppressor genes in parallel, which could account for the high frequency of p53 mutations in cancer. Implications: In this study, we investigate the activities of p53 under normal low-stress conditions and discover that p53 is capable of maintaining the expression of a group of important tumor suppressor genes at baseline, many of which are haploinsufficient, which could contribute to p53-mediated tumor suppression. Mol Cancer Res; 15(8); 1051-62. ©2017 AACR ., (©2017 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
4. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
- Author
-
Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, and Parsons R
- Subjects
- 3-Phosphoinositide-Dependent Protein Kinases, Animals, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Growth Processes physiology, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, Cell Transformation, Neoplastic pathology, Female, Gene Dosage, Humans, Mice, Mice, Inbred BALB C, Mice, SCID, Oncogene Protein v-akt metabolism, Protein Serine-Threonine Kinases biosynthesis, Protein Serine-Threonine Kinases genetics, Receptor, ErbB-2 metabolism, Signal Transduction, Breast Neoplasms enzymology, Phosphatidylinositol 3-Kinases metabolism, Protein Serine-Threonine Kinases metabolism
- Abstract
Lesions of ERBB2, PTEN, and PIK3CA activate the phosphatidylinositol 3-kinase (PI3K) pathway during cancer development by increasing levels of phosphatidylinositol-3,4,5-triphosphate (PIP(3)). 3-Phosphoinositide-dependent kinase 1 (PDK1) is the first node of the PI3K signal output and is required for activation of AKT. PIP(3) recruits PDK1 and AKT to the cell membrane through interactions with their pleckstrin homology domains, allowing PDK1 to activate AKT by phosphorylating it at residue threonine-308. We show that total PDK1 protein and mRNA were overexpressed in a majority of human breast cancers and that 21% of tumors had five or more copies of the gene encoding PDK1, PDPK1. We found that increased PDPK1 copy number was associated with upstream pathway lesions (ERBB2 amplification, PTEN loss, or PIK3CA mutation), as well as patient survival. Examination of an independent set of breast cancers and tumor cell lines derived from multiple forms of human cancers also found increased PDK1 protein levels associated with such upstream pathway lesions. In human mammary cells, PDK1 enhanced the ability of upstream lesions to signal to AKT, stimulate cell growth and migration, and rendered cells more resistant to PDK1 and PI3K inhibition. After orthotopic transplantation, PDK1 overexpression was not oncogenic but dramatically enhanced the ability of ERBB2 to form tumors. Our studies argue that PDK1 overexpression and increased PDPK1 copy number are common occurrences in cancer that potentiate the oncogenic effect of upstream lesions on the PI3K pathway. Therefore, we conclude that alteration of PDK1 is a critical component of oncogenic PI3K signaling in breast cancer.
- Published
- 2009
- Full Text
- View/download PDF
5. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
- Author
-
Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, and Parsons R
- Subjects
- Adult, Aged, Breast Neoplasms enzymology, Breast Neoplasms pathology, Cell Line, Tumor, Class I Phosphatidylinositol 3-Kinases, Cohort Studies, DNA Mutational Analysis, Estrogen Receptor alpha biosynthesis, Estrogen Receptor alpha genetics, Female, Humans, Immunohistochemistry, Lymphatic Metastasis, Middle Aged, PTEN Phosphohydrolase, Phosphoric Monoester Hydrolases genetics, Receptor, ErbB-2 genetics, Receptors, Progesterone biosynthesis, Receptors, Progesterone genetics, Tumor Suppressor Proteins genetics, Breast Neoplasms genetics, Breast Neoplasms metabolism, Mutation, Phosphatidylinositol 3-Kinases genetics, Phosphoric Monoester Hydrolases deficiency, Receptor, ErbB-2 biosynthesis, Tumor Suppressor Proteins deficiency
- Abstract
Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway either through loss of PTEN or mutation of the catalytic subunit alpha of PI3K (PIK3CA) occurs frequently in human cancer. We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV. To investigate the relationship between PTEN and PIK3CA, we generated a cohort of tumors that had lost PTEN expression and compared it with a matched control set that had retained PTEN. A highly significant association between PIK3CA mutations and retention of PTEN protein expression was observed. In addition, PIK3CA mutations were associated with expression of estrogen and progesterone receptors (ER/PR), lymph node metastasis, and ERBB2 overexpression. The fact that PIK3CA mutations and PTEN loss are nearly mutually exclusive implies that deregulated phosphatidylinositol-3,4,5-triphosphate (PIP(3)) is critical for tumorigenesis in a significant fraction of breast cancers and that loss of PIP(3) homeostasis by abrogation of either PIK3CA or PTEN relieves selective pressure for targeting of the other gene. The correlation of PIK3CA mutation to ER/PR-positive tumors and PTEN loss to ER/PR-negative tumors argues for disparate branches of tumor evolution. Furthermore, the association between ERBB2 overexpression and PIK3CA mutation implies that more than one input activating the PI3K/AKT pathway may be required to overcome intact PTEN. Thus, mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.